Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Tango Therapeutics, Inc.NASDAQ: TNGX

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $48.93M rose 58.8% year over year, ahead of the +14.3% change in trailing-twelve-month research & development. Sequentially, it rose 31.5% from the prior quarter. Over 3 fiscal years it compounded at +7.7% a year.

Context

  • Research & development amounted to 211.9% of revenue in FY2025, down 130.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +58.8% holds above the trailing-twelve-month pace of +14.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$48.93M+31.5% QoQ
Last fiscal yearDec 2025
$132.17M-8.2% YoY
LTMSep 2026
$152.48M+14.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.8%——
1 year-8.2%——
3-year CAGR+7.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
132.17M USD
Year-over-year change
-8.2%
4-year CAGR
+14.2%

Research & Development vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's LTM Sep 2026 research & development of $152.48M is the 5th highest of the 11 companies compared; the peer median is $131.23M.
  • Its year-over-year change of +14.3% is the 4th highest of 11, against a peer median of +0.5%.
  • Over three fiscal years its annual growth of +7.7% compares with a peer median of +5.7%.
TNGX Competitors Peer median
Research & Development for TNGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.29B +68.1%+57.0%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$339.54M +5.2%+52.0%150.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$270.72M -4.1%+2.0%2615.7%
TNGXTango Therapeutics, Inc.LTM Sep 2026$152.48M +14.3%+7.7%—
ERASErasca, Inc.LTM Sep 2026$133.6M +39.6%-6.2%—
NUVBNuvation Bio Inc.LTM Jun 2026$128.85M +18.2%+9.4%75.8%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M -33.8%+0.5%473.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
Peer median (excluding TNGX) $131.23M+0.5%+5.7%290.9%

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.04M24.86M36.53M42.07M62.38M
Cost of Revenue00002.28M
Gross Profit37.04M24.86M36.53M42.07M60.1M
Gross Margin100.0%100.0%100.0%100.0%96.3%
Research & Development77.64M105.91M115.2M143.92M132.17M
Selling, General & Admin17.6M30.03M35.5M43.75M41.51M
Operating Expenses95.23M135.93M150.7M187.66M171.39M
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
EBITDA(57.05M)(106.51M)(99.2M)(127.6M)(99.31M)
EBITDA Margin-154.0%-428.5%-271.6%-303.3%-159.2%
Operating Income(58.19M)(111.07M)(114.17M)(145.6M)(111.29M)
Operating Margin-157.1%-446.8%-312.6%-346.1%-178.4%
Interest Income495K1.46M6.62M7.89M5.63M
Interest Expense00000
Other Income / Expenses247K2.95M12.56M15.5M9.7M
Income Before Tax(57.94M)(108.12M)(101.61M)(130.09M)(101.59M)
Pre-Tax Margin-156.4%-434.9%-278.2%-309.2%-162.8%
Income Tax Expense292K54K134K208K4K
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Net Margin-157.2%-435.1%-278.5%-309.7%-162.9%
EPS (Basic)(0.94)(1.23)(1.08)(1.19)(0.87)
EPS (Diluted)(0.94)(1.23)(1.08)(1.19)(0.87)
Weighted Avg Shares62.11M87.82M94.57M109.23M116.17M
Weighted Avg Shares (Diluted)62.11M87.82M94.57M109.23M116.17M

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.